Lisdexamfetamine maintenance treatment for binge-eating disorder following successful treatments: randomized double-blind placebo-controlled trial
Grilo C, Ivezaj V, Yurkow S, Tek C, Wiedemann A, Gueorguieva R. Lisdexamfetamine maintenance treatment for binge-eating disorder following successful treatments: randomized double-blind placebo-controlled trial. Psychological Medicine 2024, 54: 3334-3344. PMID: 39258475, PMCID: PMC11496227, DOI: 10.1017/s003329172400148x.Peer-Reviewed Original ResearchEating-disorder psychopathologyBinge-eating disorderMaintenance treatmentAcute treatmentBinge-eating remission ratesCognitive-behavioral therapyEfficacy of lisdexamfetamineSignificant weight gainDouble-blind placebo-controlled trialAcute respondersLisdexamfetamine treatmentPsychopathological outcomesPosttreatment assessmentLisdexamfetaminePlacebo-controlled trialRandomized double-blind placebo-controlled trialSingle-site trialAssociated with significant weight lossPsychopathologyBinge-eatingRemission rateWeight lossPlaceboRelapse rateControl researchOvervaluation of shape/weight at posttreatment predicts relapse at 12‐month follow‐up after successful behaviorally‐based treatment of binge‐eating disorder
Grilo C, Ivezaj V, Gueorguieva R. Overvaluation of shape/weight at posttreatment predicts relapse at 12‐month follow‐up after successful behaviorally‐based treatment of binge‐eating disorder. International Journal Of Eating Disorders 2024, 57: 1268-1273. PMID: 38321617, PMCID: PMC11093697, DOI: 10.1002/eat.24141.Peer-Reviewed Original ResearchOvervaluation of shape/weightEating-disorder psychopathologyBinge-eating disorderEating Disorder Examination interviewBeck Depression InventoryWeight loss treatmentClinical overvaluationBinge-eating frequencyDiagnostic specifierBinge eatingNon-abstinenceExamination interviewDepression InventoryShape/weightDepression scoresFollow-upPsychopathologyAbstinenceBingeDepressionClinical implicationsDepression 1PosttreatmentDisordersOvervaluation